DVAX
Price
$10.06
Change
+$0.08 (+0.80%)
Updated
Sep 5 closing price
Capitalization
1.18B
54 days until earnings call
SUPN
Price
$46.00
Change
+$0.57 (+1.25%)
Updated
Sep 5 closing price
Capitalization
2.58B
66 days until earnings call
Interact to see
Advertisement

DVAX vs SUPN

Header iconDVAX vs SUPN Comparison
Open Charts DVAX vs SUPNBanner chart's image
Dynavax Technologies
Price$10.06
Change+$0.08 (+0.80%)
Volume$1.42M
Capitalization1.18B
Supernus Pharmaceuticals
Price$46.00
Change+$0.57 (+1.25%)
Volume$657.58K
Capitalization2.58B
DVAX vs SUPN Comparison Chart in %
Loading...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DVAX vs. SUPN commentary
Sep 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DVAX is a Hold and SUPN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 07, 2025
Stock price -- (DVAX: $10.06 vs. SUPN: $46.00)
Brand notoriety: DVAX and SUPN are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: DVAX: 89% vs. SUPN: 77%
Market capitalization -- DVAX: $1.18B vs. SUPN: $2.58B
DVAX [@Pharmaceuticals: Generic] is valued at $1.18B. SUPN’s [@Pharmaceuticals: Generic] market capitalization is $2.58B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DVAX’s FA Score shows that 0 FA rating(s) are green whileSUPN’s FA Score has 0 green FA rating(s).

  • DVAX’s FA Score: 0 green, 5 red.
  • SUPN’s FA Score: 0 green, 5 red.
According to our system of comparison, SUPN is a better buy in the long-term than DVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DVAX’s TA Score shows that 3 TA indicator(s) are bullish while SUPN’s TA Score has 3 bullish TA indicator(s).

  • DVAX’s TA Score: 3 bullish, 4 bearish.
  • SUPN’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, SUPN is a better buy in the short-term than DVAX.

Price Growth

DVAX (@Pharmaceuticals: Generic) experienced а -0.59% price change this week, while SUPN (@Pharmaceuticals: Generic) price change was +1.95% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.10%. For the same industry, the average monthly price growth was +12.13%, and the average quarterly price growth was +87.01%.

Reported Earning Dates

DVAX is expected to report earnings on Oct 30, 2025.

SUPN is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.10% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SUPN($2.58B) has a higher market cap than DVAX($1.18B). DVAX has higher P/E ratio than SUPN: DVAX (54.60) vs SUPN (40.00). SUPN YTD gains are higher at: 27.212 vs. DVAX (-21.222). SUPN has higher annual earnings (EBITDA): 174M vs. DVAX (-34.26M). DVAX has more cash in the bank: 614M vs. SUPN (523M). SUPN has less debt than DVAX: SUPN (31.8M) vs DVAX (285M). SUPN has higher revenues than DVAX: SUPN (665M) vs DVAX (316M).
DVAXSUPNDVAX / SUPN
Capitalization1.18B2.58B46%
EBITDA-34.26M174M-20%
Gain YTD-21.22227.212-78%
P/E Ratio54.6040.00137%
Revenue316M665M48%
Total Cash614M523M117%
Total Debt285M31.8M896%
FUNDAMENTALS RATINGS
DVAX vs SUPN: Fundamental Ratings
DVAX
SUPN
OUTLOOK RATING
1..100
5818
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
78
Overvalued
PROFIT vs RISK RATING
1..100
8639
SMR RATING
1..100
9480
PRICE GROWTH RATING
1..100
8239
P/E GROWTH RATING
1..100
97100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DVAX's Valuation (69) in the Biotechnology industry is in the same range as SUPN (78) in the Pharmaceuticals Other industry. This means that DVAX’s stock grew similarly to SUPN’s over the last 12 months.

SUPN's Profit vs Risk Rating (39) in the Pharmaceuticals Other industry is somewhat better than the same rating for DVAX (86) in the Biotechnology industry. This means that SUPN’s stock grew somewhat faster than DVAX’s over the last 12 months.

SUPN's SMR Rating (80) in the Pharmaceuticals Other industry is in the same range as DVAX (94) in the Biotechnology industry. This means that SUPN’s stock grew similarly to DVAX’s over the last 12 months.

SUPN's Price Growth Rating (39) in the Pharmaceuticals Other industry is somewhat better than the same rating for DVAX (82) in the Biotechnology industry. This means that SUPN’s stock grew somewhat faster than DVAX’s over the last 12 months.

DVAX's P/E Growth Rating (97) in the Biotechnology industry is in the same range as SUPN (100) in the Pharmaceuticals Other industry. This means that DVAX’s stock grew similarly to SUPN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DVAXSUPN
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
67%
N/A
Momentum
ODDS (%)
Bearish Trend 2 days ago
74%
N/A
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
64%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 25 days ago
75%
Bullish Trend 2 days ago
75%
Declines
ODDS (%)
Bearish Trend 5 days ago
78%
Bearish Trend 5 days ago
64%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
N/A
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MOWNX20.910.26
+1.26%
Moerus Worldwide Value N
CDIVX12.76N/A
N/A
Copeland Dividend Growth Fund Class I
SCSDX18.74N/A
N/A
Allspring Common Stock Admin
TEQLX12.96N/A
N/A
Nuveen Emerging Markets Eq Idx R6
BMSSX15.33N/A
N/A
MFS Blended Research Mid Cap Eq R2

DVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, DVAX has been loosely correlated with ACET. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if DVAX jumps, then ACET could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DVAX
1D Price
Change %
DVAX100%
+0.80%
ACET - DVAX
39%
Loosely correlated
+1.00%
SNDL - DVAX
35%
Loosely correlated
+1.64%
BCRX - DVAX
33%
Poorly correlated
N/A
AMRX - DVAX
33%
Poorly correlated
+0.73%
ESPR - DVAX
32%
Poorly correlated
+5.93%
More